Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate

European Journal of Haematology

Volumn 73, Issue 2, 2004, Pages 147-148

  Stagno, Fabio ^a   Consoli, Carla ^a   Mannino, Francesca ^a   Guglielmo, Patrizia ^a   Giustolisi, Rosario ^a  

^a Ospedale Ferrarotto   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB;

ADULT; ANAMNESIS; BONE MARROW EXAMINATION; CASE REPORT; CLINICAL FEATURE; CLONAL VARIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FLUID RETENTION; HEPATOSPLENOMEGALY; HUMAN; LABORATORY TEST; LETTER; MALE; MUSCULOSKELETAL DISEASE; MYELOID METAPLASIA; PRIORITY JOURNAL; SWITZERLAND;

CYTOGENETIC ANALYSIS; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 3242802875     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00264.x     Document Type: Letter

References (10)

1. TEFFERI A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
2. BAROSI G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-2970.
3. DUPRIEZ B, MOREL P, DEMORY JL, LAI JL, SIMON M, PLANTIER I, BAUTERS F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
4. TEFFERI A, MESA RA, GRAY LA et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002;99:3854-3856.
5. CORTES J, GILES F, O'BRIEN S et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003;97:2760-2766.
6. HASSELBALCH HC, BJERRUM OW, JENSEN BA, CLAUSEN NT, HANSEN PB, BIRGENS H, THERKILDSEN MH, RALFKIAER E. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 2003;74:238-242.
7. REILLY JT. Pathogenesis and management of idiopathic myelofibrosis. Baillieres Clin Haematol 1998;11:751-767.
8. SIITONEN T, SAVOLAINEN ER, KOISTINEN P. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodisplastic syndromes. Leukemia 1994;8:631-637.
9. BUCHDUNGER E, CIOFFI CL, LAW N, STOVER D, OHNO-JONES S, DRUKER BJ, LYDON NB. Ab1 protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
10. BEHAM-SCHMID C, APFELBECK U, SILL H, TSYBROVSKY O, HOFLER G, HAAS OA, LINKESCH W. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 2002;99:381-383.